Northern Communities Lecture
Professor Michael Nauck
Professor Michael Nauck
New treatments for type 2 diabetes to decrease the risk of heart disease and prolong life
In this public lecture, Professor Michael Nauck expounds on the type 2 diabetes research he developed over the last 25 years. The first researcher to recognise the potential of the hormone GLP-1 for treating patients with type 2 diabetes, Professor Nauck has helped millions of people world-wide with type 2 diabetes by reducing their risk of heart disease and other metabolic conditions. He is currently the Head of Clinical Research at the Diabetes Division, Medical Department I, St. Josef-Hospital (Ruhr-University Bochum) in Bochum, Germany.
Professor Nauck was the first researcher who recognised the potential of the hormone GLP-1 for treating patients with type 2 diabetes. The hormone was discovered by Professor Jens Juul Holst in 1987, and in 1993, Professor Nauck showed the potential of the new hormone for treating type 2 diabetes which led to the development of incretin-based treatment. Through collaborating with Carolyn Deacon and Professor Jens Juul Holst, the proteolytic degradation of GLP-1 with the DPP-4 enzyme was demonstrated for the first time in humans, which led to the development of DPP 4-inhibitors which are now used all over the world.
Professor Nauck has been honoured with several awards for his research, including the Ferdinand-Bertram Award (1993), the Werner-Creutzfeldt Award (2007) and the Paul Langerhans Medal (2012) of the Deutsche Diabetes-Gesellschaft (German Diabetes Association) and is member of a number of professional societies, including the German, European and American Diabetes Associations, and the International Diabetes Federation.
An area of particular interest for Professor Nauck has been the incretin effect. The incretin effect describes the phenomenon whereby oral glucose elicits higher insulin secretory responses than does intravenous glucose, despite inducing similar levels of glycaemia, in healthy individuals. This effect, which is uniformly defective in patients with type 2 diabetes, is mediated by the gut-derived incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).
Lecture Recording: New treatments for type 2 diabetes
Recorded 21 March 2016 at the University of Adelaide